ANSTO Nuclear Medicine Project

Jayne Senior,

General Manager, ANSTO Nuclear Medicine.

1 pm Thursday 25 August,

AINSE Theatre, Lucas Heights, NSW.

Meeting hosted by ANA.

Click here to see slides of Jayne Senior’s Presentation

ANSTO Nuclear Medicine2
Artists Impression of completed nuclear medicine production facility


In 2012, the Australian Government announced a $168.8 million investment that will position Australia as a global leader in the manufacture of nuclear medicine.

The ANSTO Nuclear Medicine (ANM) Project will enable ANSTO to triple production of Molybdenum-99 (Mo-99). The increased capacity will enable Australia to meet domestic demand, as well as being able to supply up to 25-30% of global demand. Used for 80 per cent of nuclear medicines, Mo-99 decays to Tc-99m which is the base material used in the diagnosis of cancers, heart disease, muscular and skeletal conditions. Construction of Australia’s new nuclear medicine production facility began in mid 2014 and remains on target for completion in 2016.

This presentation will provide an update on the ANM project, its objectives and the status of construction, including any special considerations for the radiopharmaceutical production facility.


About Jayne Senior:
Jayne Senior is an executive at the Australian Nuclear Science and Technology Organisation (ANSTO). She is General Manager of ANSTO Nuclear Medicine (ANM) Pty Ltd, overseeing the transition from construction to operation of the $169 million ANSTO Nuclear Medicine project.

Senior has more than 13 years of experience in chief executive, managing director and general manager positions with global companies operating in complexly regulated industries. Prior to taking this role she was the General Manager of Genetics Australia, Australia’s largest artificial breeding supplier, where Senior oversaw and implemented effective strategic directions for business.

Previously, in her role as Managing Director of Paton’s Macadamias Australia, Senior identified and implemented growth plans locally and globally. Senior has also held positions at director and executive level at Mentholatum Australasia, Novartis Consumer Health UK & Eire, Treasures Babycare Australasia (Carter Holt Harvey), Novartis Consumer Health Australasia and Kraft Foods Australia.

With an academic grounding in science, genetics, bio-aeronautics and marketing, Senior balances innovation and problem solving with detail orientation and the pragmatic application of business strategy. Senior has diverse and expansive experience in industries that are highly regulated and which cover wide geographical regions. This well equips her to tackle ANSTO’s further forays into the $8 billion nuclear medicine business, and deliver more Australian nuclear medicine to the world through her position as General Manager of ANM.